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Abstract
Background:  Matrix metalloproteinases (MMPs) are a family of structural and functional related
endopeptidases. They play a crucial role in tumor invasion and building of metastatic formations because
of their ability to degrade extracellular matrix proteins. Under physiological conditions their activity is
precisely regulated in order to prevent tissue disruption. This physiological balance seems to be disrupted
in cancer making tumor cells capable of invading the tissue. In breast cancer different expression levels of
several MMPs have been found.
Methods: To fill the gap in our knowledge about MMP expression in breast cancer, we analyzed the
expression of all known human MMPs in a panel of twenty-five tissue samples (five normal breast tissues,
ten grade 2 (G2) and ten grade 3 (G3) breast cancer tissues). As we found different expression levels for
several MMPs in normal breast and breast cancer tissue as well as depending on tumor grade, we
additionally analyzed the expression of MMPs in four breast cancer cell lines (MCF-7, MDA-MB-468, BT
20, ZR 75/1) commonly used in research. The results could thus be used as model for further studies on
human breast cancer. Expression analysis was performed on mRNA and protein level using
semiquantitative RT-PCR, Western blot, immunohistochemistry and immunocytochemistry.
Results: In summary, we identified several MMPs (MMP-1, -2, -8, -9, -10, -11, -12, -13, -15, -19, -23, -24,
-27 and -28) with a stronger expression in breast cancer tissue compared to normal breast tissue. Of
those, expression of MMP-8, -10, -12 and -27 is related to tumor grade since it is higher in analyzed G3
compared to G2 tissue samples. In contrast, MMP-7 and MMP-27 mRNA showed a weaker expression in
tumor samples compared to healthy tissue. In addition, we demonstrated that the four breast cancer cell
lines examined, are constitutively expressing a wide variety of MMPs. Of those, MDA-MB-468 showed the
strongest mRNA and protein expression for most of the MMPs analyzed.
Conclusion: MMP-1, -2, -8, -9, -10, -11, -12, -13, -15, -19, -23, -24, -27 and -28 might thus be associated
with breast cancer development and tumor progression. Therefore, these MMPs are proper candidates
for further functional analysis of their role in breast cancer.
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Background
Breast cancer is the most common cancer affecting women
in the world today. It is the leading cause of cancer related
death for women aged between 35 and 55 years world-
wide. One in nine women will suffer from breast cancer
during her life and in excess 130 thousand women die
from breast cancer each year [1]. According to histological
features invasive breast cancers are classified into three
groups: well differentiated (grade 1, G1), moderately dif-
ferentiated (grade 2, G2) and poorly differentiated (grade
3, G3) tumors. Distant metastases are the principal cause
of death. An essential process in forming distant metas-
tases is the degradation of the extracellular matrix allow-
ing tumor cells to invade local tissue, intravasate and
extravasate blood vessels and build new metastatic forma-
tions. This process is primarily influenced by the activity
of proteinases secreted by the tumor. Currently, at least
four classes of proteinases are known: serine proteinases,
aspartatic proteinases, cystein proteinases and matrix met-
alloproteinases [2-4]. Collectively, these proteinases are
capable of breaking down all components of the extracel-
lular matrix. Under physiological conditions (e.g. tissue
remodeling, angiogenesis, ovulation, wound healing)
there is a precise regulation between proteolytic degrada-
tion and regulatory inhibition of proteolysis [2-5]. This
physiological balance seems to be disrupted in cancer.
Matrix metalloproteinases (MMPs) are up regulated in
almost every type of cancer and their expression is often
associated with a poor prognosis for patients [6,7]. Previ-
ous studies have shown the expression and activity of
MMPs to be linked to an advanced stage of breast cancer,
increased invasion of tumour cells and building of meta-
static formations [reviewed in [8]].
MMPs are a family of structural and functional related
endopeptidases. They are, with exception of MMP-11,
secreted as inactive zymogens and activated outside the cell
by other activated MMPs or serine proteases (e.g trypsin,
plasmin, kallikrein) [2-4]. For their activation, a proteolytic
removal of the propeptide-domain is required. This enables
access to the catalytic site of the MMPs. The cleavage of the
extracellular matrix (ECM) by activated MMPs facilitates
the invasion of tumor cells as well as the release of ECM
bound growth factors (e.g. of insulin like growth factors
and fibroblast growth factors). Further, some of the result-
ing ECM-protein fragments can feature new biological
functions (e.g. cleavage of laminin-5 or collagen type IV
results in uncovering of their cryptic site which can pro-
mote migration of different cell types) [2-4].
Currently, 23 members of the MMP family are known in
humans. According to their substrate specificity, they are
divided into six subclasses: collagenases, gelatinases,
stromelysins, matrilysins, membrane-type MMPs and oth-
ers [2]. So far, most investigators have focused on the
expression profile of the two gelatinases, MMP-2 and
MMP-9, which are able to degrade type IV collagen. [9-
11]. Type IV collagen is abundant in basement mem-
branes separating the epithelial cells from the underlying
stroma. Increased expression and activity of MMP-2 and -
9 in tumors leads to the degradation of basement mem-
branes, an essential step in tumor invasion. In this respect,
a correlation between a high expression of MMP-2 and
reduced survival in breast cancer patients [12] as well as
an association of the tumor grade with increased levels of
MMP-9 in breast cancer tissue [13] was described. Effi-
cient reduction of MMP-2 and -9 levels was observed dur-
ing in vitro treatment of MCF-7 breast cancer cells with the
aromatase-inhibitor letrozole suggesting that this inhibi-
tor suppresses both breast cancer growth and invasion
[14].
For MMP-1, -7, -9, -13 and -14 an association between
their high expression and a shortened relapse free survival
in breast cancer patients was found [15]. A high expres-
sion of MMP-9 and -11 in breast cancer tissue was also
detected by Northern blot analysis [16]. Vizoso et al.
showed a correlation between high expression levels of
these two MMPs and a higher rate of distant metastases
using immunohistochemistry [15]. In addition, the
expression of MMP-2, -8, -9, -10, -11 and -13 mRNA in
breast cancer tissue was identified by RT-PCR [17].
Gonzalez et al. found MMP-1, -7 and -13 to be expressed
at higher levels in androgen receptor positive breast cancer
cells using immunohistochemistry [18]. This suggests,
that androgen receptors might be able to up regulate
MMPs and contribute to a higher invasive potential of
breast cancer cells. Using Northern Blot analysis, a higher
expression of MMP-2, -7, -9 and -11 mRNA was shown in
breast cancer tissue in comparison to normal breast tissue
[19]. In addition, a higher content of MMP-1 and -9 pro-
tein was detected in breast cancer tissue when compared
to normal breast tissue by ELISA technique [20]. Using
substrate zymography, MMP-1, -2, -3 and -9 demon-
strated a higher activity in tumor tissues compared to
healthy samples [5]. Expression of MMP-3 was shown to
be higher in stromal tissue surrounding the epithelial
tumor cells than in tumor cells themselves [21]. A correla-
tion between positive nodal status and the expression of
MMP-14 and -15 mRNA was found by Ueno et al. [22].
Haupt et al. found MMP-14 to be expressed predomi-
nantly in preinvasive lesions of breast cancer using RT-
PCR [21]. To our knowledge, currently there are no data
available for the remaining MMPs regarding their expres-
sion in breast cancer tissue in literature.
Thus, the aim of our study was to investigate, if a pattern
of MMPs could be identified, whose expression is related
to tumor grade in breast cancer. With this objective, we
analyzed the expression of all human MMPs known so farBMC Cancer 2009, 9:188 http://www.biomedcentral.com/1471-2407/9/188
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in a panel of normal breast and breast cancer samples by
semiquantitative RT-PCR, Western Blot and immunohis-
tochemistry. Further, in order to create an independent
and reproducible model system for the in vitro analysis of
the regulation of MMP expression in breast cancer cells,
we analyzed the MMP-pattern in four breast cancer cell
lines frequently used in basic breast cancer research (MCF-
7, BT-20, MDA-MB-468, ZR 75/1). For an overview, data
concerning MMP expression in breast cancer cell lines
published so far are summarized in Additional file 1:
MMP expression in different breast cancer cell lines [23-
27].
Methods
Tissue samples
The study was performed with approval of the Ethics
Committee of the University of Wuerzburg, Germany. To
establish an expression profile of MMPs typical for breast
cancer, we compared normal breast tissue to breast cancer
tissue with higher grading (G2 and G3). We excluded
well-differentiated breast cancer (G1) tissue, because
material of G1-tumors was rare. MMP expression was ana-
lyzed in five normal breast and twenty breast cancer tissue
samples. The normal breast tissue samples were obtained
from patients who underwent reductive mammoplasty for
cosmetic reasons (tissue was analyzed histologically to
exclude that there were any forms of malignancy or other
pathological findings; data not shown). Written informed
consent was obtained from each patient according to our
institutional regulations. Twenty samples of breast cancer
tissue (ten G2 and ten G3 tumors) were obtained during
surgical removal of the tumor at the department of Gynae-
cology and Obstetrics at the University Hospital of Wuerz-
burg, Germany. Some parts of the samples were
immediately frozen in liquid nitrogen and stored at -
80°C, other parts were fixed in formalin and embedded in
paraffin. Patients' data are listed in Table 1. Tissue was
selected in order to contain approximately equal amounts
of stromal tissue (as analyzed by HE-staining). Therefore
stroma was present to nearly the same extent in each tissue
sample that was analyzed by RT-PCR and Western blot
analysis. Tissue samples were examined for content of
benign and/or malign glandular tissue by HE-staining
also. Only samples with high density of benign lobuli/
acini or tumour cell mass without signs of necrosis were
used for further analysis.
Cell culture
Cell lines (MCF-7, MDA-MB-468, BT 20, ZR 75/1) were
obtained from Cell Lines Service (Eppelheim, Germany)
[28]. Characteristics of the cell lines are listed in Table
2[29-36]. Briefly, cells were cultured in a mixture of
DMEM/Ham's F-12 (PAA, Coelbe, Germany) supple-
mented with 10% FCS and 10 ng/ml gentamycine at 37°C
in the presence of 5% CO2. Cells were cultured in 75 ml
culture-flasks (Biochrom, Berlin, Germany) as monolayer
culture and harvested at 80–90% confluency using a cell-
scraper (Biochrom) or accutase (PAA) treatment. Sepa-
rated cells were resuspended in phosphate-buffered saline
(PBS) and washed twice. Cells were then counted and
checked for viability using trypan blue and either sub-
jected to immunocytochemistry or immediately frozen as
Table 1: Patients data
G2-tumors
(n = 10)
G3-tumors
(n = 10)
age at diagnosis (y)
mean 64,7 71,8
minimum 42 52
maximum 91 90
T (tumor size)
14 3
25 2
3- -
41 5
N (nodal status)
06 1
12 5
21 2
X1 2
M
01 0 6
1- 4
L
07 2
13 8
multifocal 4 3
inflammatory 1 4
invasive ductal 8 9
invasive ductal +DCIS 2 -
invasive lobular - 1
receptor status
ER +/PR+ 3 4
ER +/PR - 1 1
ER -/any PR 5 3
n.d. 1 2
Her2neu 2+/3+ 2 3
Her2neu negative 5 2
n.d. 3 5
G1 = well differentiated tumor; G2 = moderatly differentiated tumor; 
G3 = poorly differentiated tumor (the three-tier grading system (G1-
3) is usually used at our institution to determine the histologic grade 
of tumor tissue). T = tumor grade; N = nodal status; M = distant 
metastasis; L = invasion of lymphatic vessels; DCIS = ductal carcinoma 
in situ; ER = estrogen receptor; PR = progesterone receptor; n.d. = 
not done.BMC Cancer 2009, 9:188 http://www.biomedcentral.com/1471-2407/9/188
Page 4 of 20
(page number not for citation purposes)
dry pellets at -20°C for further analysis. All cell prepara-
tions used had a viability of >95%.
RNA extraction and cDNA synthesis
Frozen blocks (1 cm2) of normal and tumor tissue were
cut into sections of 6 μm; sections corresponding to 30 mg
were collected in a sterile microtube and subjected to RNA
isolation. In case of cultured cell lines, 106 cells were used
for RNA extraction. Total RNA was extracted using RNeasy
mini kit (Qiagen, Hilden, Germany) according to the
manufacturers' instruction. RNA was eluted in 60 μl
RNase free water and stored at -20°C. Total RNA was
reverse transcribed at 42°C for 1 h in a 20 μl reaction mix-
ture using the RevertAid H Minus First Strand cDNA syn-
thesis kit (Fermentas, St. Leon-Roth, Germany) and
terminated by heating the samples at 70°C for 10 min.
Synthesized cDNA was stored at -20°C for further expres-
sion analysis.
Semiquantitative RT-PCR
Expression analysis of MMPs was performed using self-
created gene specific primers. Primer sequences and PCR
conditions are summarized in Additional File 2. In gen-
eral, conventional PCR reaction was performed in 25 μl
volumes containing template DNA, 2.5 U Taq polymer-
ase, 10× buffer with 1.5 mM MgCl2 (all Eppendorf, Ham-
burg, Germany), 200 μM dNTPs (Fermentas), 0.4 μM of
both, forward and reverse primers and formamide, which
was used optionally at a final concentration of 4%. PCR
conditions were optimized for each primer-pair. Amplifi-
cation reactions were performed using a Px2 thermal
cycler (Techne, Staffordshire, U.K.) and consisted of fol-
lowing steps: 94°C for 5 min, 28–32 cycles at 94°C for 30
sec; optimized annealing temperatures for 30 sec and
72°C for 10 min. The amount of cDNA was normalized
to the intensity of the PCR products of the housekeeping
gene (PBGD) [37]. All PCR products were separated on
1% agarose gels and visualized using GelRed (Biotium,
Inc., Hayward, CA). Intensity of GelRed luminescence was
measured using ImageJ software (NIH, Bethesda, USA).
All RT-PCRs were performed in triplicates.
Western blotting
For protein extraction, 20 mg of cryo-cut tissue samples or
respectively 106 cells were lysed in pre-cooled Ripa-buffer
(Pierce, Rockford, Ilinois) containing phosphatase inhib-
itors (Phosphatase Inhibitor Cocktails Set II, Calbiochem,
Germany), proteinase inhibitors (complete, Roche, Ger-
many) and 2,5 mM DTT (Dithiothreitol, Sigma,
Taufkirchen, Germany) as reducing agent. The mixture
was incubated on ice for 30 min, combined with vortexing
every 10 min. Cell lysates were clarified of cell debris by
centrifugation at 14.000 g for 5 min through a QIAshred-
der spin column assembly (Qiagen, Hilden, Germany).
Afterwards, the samples were mixed in 5× loading buffer
(Fermentas), denatured at 95°C for 5 min, chilled on ice
and stored at -20°C for further analysis.
Protein concentration was determined by the Bradford-
method [38] using comassie brilliant blue (Roti-Quant;
Roth, Karsruhe, Germay). Samples were subjected to elec-
trophoresis on a 10% polyacrylamide gel (SDS-PAGE)
and blotted onto a nitrocellulose membrane (Schleicher
& Schuell, Dassel, Germany) for 45 min at 10 V using a
semi-dry-transfer unit (PeqLab, Erlangen, Germany).
Membranes were stained with ponceau-red to verify that
the proteins were blotted. To avoid non-specific binding,
membranes were blocked with 5% nonfat milk protein in
PBS/Tween at RT for 1 hour. Subsequently, the mem-
branes were incubated with the primary antibody diluted
in 2% nonfat milk and PBS/Tween at 4°C for 18 hours. As
internal loading control, anti-β-actin primary antibody
was used. Clones, sources and dilutions of the primary
antibodies used herein are summarized in Table 3. After
washing with PBS, the membranes were incubated with
species specific horseradish peroxidase-conjugated sec-
ondary antibodies (listed in Table 3) for 60 min at RT.
Immunoblots were visualized by home made "enhanced
Table 2: Cell lines
Cell line MCF-7 MDA-MB 468 BT 20 ZR 75/1
Cell type Adeno-carcinoma Adeno-carcinoma Invasive ductal carcinoma Adeno-carcinoma
Origin Metastasis (pleural effusion) Metastasis (pleural effusion) Primary tumor Metastasis (ascites fluid)
Estrogen-/progesterone-
receptor
+/+ -/- -/- +/+
Invasive potential Low Low Low -
Metastatic potential -/+ Low - -
Table based on data published previously [29-36]BMC Cancer 2009, 9:188 http://www.biomedcentral.com/1471-2407/9/188
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chemiluminescence" ECL [39]. Resulting images were
quantified using ImageJ software (NIH, Bethesda, USA).
Immunohistochemistry
For immunohistochemistry, tissue samples were cut at 2
μm from formalin-fixed, paraffin-embedded tissue
blocks, placed on adhesive treated slides (Superfrost, Lan-
genbrinck, Emmendingen, Germany) and dried overnight
at room temperature. Paraffin sections were dewaxed
twice with xylene and rehydrated in a graded series of eth-
anol and in distilled water. The sections were stained
without pretreatment for antigen demasking. Only in the
case of MMP-19, slides were pretreated in the microwave
oven in a 10 mM sodium citrate buffer solution (pH 6.0)
for 10 minutes (750 W/s). Endogenous peroxidase activity
was blocked with 0.3% hydrogen peroxide in methanol
for 10 minutes. To reduce non-specific binding capacity of
the tissue, slides were treated with a solution of human
immunoglobulin (Beriglobin; Aventis Behring, Marburg,
Germany) in phosphate buffered saline (PBS, dilution
1:50) for 15 minutes at room temperature. Afterwards the
sections were incubated overnight at 4°C with one of the
Table 3: Antibodies for Western blot and immunohistochemistry
Gene Application Protein forms detected 
by WB
Species Type/clone Dilution In WB Dilution in IHC-P and 
ICC
Company
MMP-1 WB, IHC latent and active rabbit polyclonal 1:750 1:100 Biozol
MMP-2 WB, IHC latent and active rabbit polyclonal 1: 1000 1:100 Abcam
MMP-3 WB, IHC, ICC latent and active mouse SPM 293 1: 500 1:50 Abcam
MMP-7 WB latent and active mouse 111433 1: 500 - Abcam
MMP-8 WB latent and active mouse 115-13D2 1: 1000 - Chemicon
MMP-9 WB latent and active mouse 9D4.2 1: 500 - Chemicon
MMP-10 WB, IHC, ICC latent and active mouse IVC5 1: 500 1:100 Chemicon
MMP-11 WB latent and active mouse SL 3.01 1: 500 - Abcam
MMP-11 IHC, ICC latent and active mouse SPM 199 - Prediluted Biozol
MMP-12 WB latent and active rabbit polyclonal 1: 1000 - Abcam
MMP-13 WB, IHC latent and active mouse 87512 1: 500 1:100 R&D
MMP-14 WB, IHC, ICC latent and active rabbit polyclonal 1: 500 1:75 Abcam
MMP-15 WB, IHC, ICC latent and active rabbit polyclonal 1: 500 1:100 Abcam
MMP-19 WB latent and active rabbit polyclonal 1: 3000 - Biozol
MMP-19 IHC, ICC latent and active rabbit polyclonal - Prediluted Biozol
MMP-23 WB latent and active rabbit polyclonal 1: 1000 - Abcam
MMP-24 WB latent and active rabbit polyclonal 1: 1000 - Abcam
MMP-27 WB not specified rabbit polyclonal 1: 1000 - Abcam
MMP-28 WB not specified rabbit polyclonal 1: 1000 - Abcam
β-actin WB b-actin mouse M/Abcam 8226 1: 10.000 - Abcam
WB: Western blot; IHC-P: Immunohistochemistry (formalin-fixed paraffin-embedded section),
ICC: ImmunocytochemistryBMC Cancer 2009, 9:188 http://www.biomedcentral.com/1471-2407/9/188
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respective primary antibodies against MMP-1, -2, -3, -10,
-11, -13, -14, -15 and -19 diluted in antibody diluent
(DAKO, Hamburg, Germany; antibodies are listed in
Table 3). The other antibodies listed in Table 2 did not
produce sufficient staining results for immunohistochem-
istry and could therefore not be analyzed herein. After
washing with PBS, the sections were incubated with
horseradish-peroxidase (HRP)-labeled LSAB2 kit (strepta-
vidin-biotin system; DAKO). Peroxidase activity was
developed with diaminobenzidine (DAB; DCS, Hamburg,
Germany) as a substrate for 5 min, which resulted in
brown staining. The slides were counterstained with hae-
matoxylin, dehydrated in graded ethanol, embedded in
Vitro Clud (Langenbrinck) and analyzed using a light
microscope Othoplan (Leica, Germany).
Immunocytochemistry
For immunocytochemistry, cells harvested with accutase
were diluted at 1 × 106 cells/ml. 20 μl of each cell line was
applied on APES-treated slides, air dried and fixed in a 2%
formalin solution (diluted in PBS) for 15 min. Cells were
then permeabilized by incubation in 0.05% Triton X100
in PBS for 10 min followed by a single wash in PBS. Block-
ing of non-specific binding capacities, incubation and
detection of primary antibodies as well as counterstaining
and embedding was performed as described for immuno-
histochemistry. All incubation steps apart from the pri-
mary antibodies were carried out at room temperature.
Antibodies were validated for this staining technique
using cell lines of different cancer sources (breast, cervix,
placenta, ovary and endometrium) with known MMP
expression in RT-PCR and/or WesternBlot. With the stain-
ing protocol applied, only MMP-3, -11, -14, -15 and -19
produced reproducible results.
Data analysis and statistics
The intensity of GelRed luminescence and protein expres-
sion in Western Blot images was quantified densitometri-
cally using ImageJ software (NIH, Bethesda, USA) and
normalized in respect to the corresponding fragment con-
centration of the ubiquitously expressed genes PBGD and
β-actin. Four different expression levels were considered
in respect of their densitometrical value. Value 0 was con-
sidered to be no expression. Values between 1 and 19 were
considered as very weak ((+)), between 20 and 49 as weak
(+), between 50 and 79 as moderate (++) and between 80
and 100 as high (+++) expression.
Box-plots were generated using GraphPad Prism 4.0
Software (GraphPad Software, La Jolla, USA). Compari-
son of expression values between the groups was per-
formed by the non-parametric two-tailed Mann-
Whitney-U-test and P-values < 0.05 were considered as
statistically significant.
Results
Patients' data
We analyzed ten tissue samples of both, grade 2 (G2) and
grade 3 (G3) breast cancer tissues. Altogether, patients
with grade 3 tumors had a bigger tumor size (T). Further-
more, more patients with G3 tumors had lymph node
metastases at the time of the initial diagnosis (7 in G3 vs.
3 in G2 group) or lymphangiosis (8 patients in the G3 vs.
2 patients in the G2 group; Table 1a). Patients of the G2-
tumor group were younger than patients in the G3-tumor
group (64 vs. 71 years) at initial diagnosis. Concerning
tumor type and receptor-status no differences between the
two groups were found (Table 1).
Expression of MMP mRNA in normal breast tissue and 
breast cancer tissue
Results of the semiquantitative RT-PCR are summarized
in Figure 1 and boxplot analysis of densitometrically
quantified expression of MMPs in Figure 2. P-values are
listed in Table 4. Except for MMP-20 and -26, the mRNA
of all other MMPs was detected in breast cancer tissue as
well as in normal breast tissue. In summary, three differ-
ent mRNA expression patterns could be observed compar-
ing normal and malign breast tissue.
MMPs with higher expression in breast cancer tissue
Significantly higher mRNA expression in breast cancer tis-
sue in contrast to normal breast tissue was detected for
MMP-1, -9, -11, -13 and -28 (Figure 1, Table 4). Expres-
sion of MMP-1 mRNA was higher in breast cancer tissue
grade 2 than in normal breast tissue (p = 0,0027) (Figure
2, Table 4). Similar significant differences between nor-
mal breast tissue and grade 2 breast cancer tissue concern-
ing the mRNA levels were observed for MMP-9 (p =
0,0127), MMP-11 (p = 0,0007) and MMP-13 (p = 0,008)
(Figure 2). Furthermore MMP-9, -11 and -28 mRNA
expression was higher in breast cancer tissue grade 3 than
in normal breast tissue (Figure 1 and 2, Table 4). MMP-1
and -13 also showed a higher expression of mRNA in
grade 3 breast cancer tissue compared to normal breast tis-
sue, but these differences were not statistically significant.
Except for MMP-9 and -12 there was no statistically signif-
icant difference in the mRNA expression profile of the
remaining three MMPs between G2 and G3 breast cancer
tissues. For MMP-9, a higher amount of mRNA was
detected in grade 2 breast cancer tissue when compared to
grade 3 breast cancer tissue (p = 0,023) (Figure 2).
MMPs with lower expression in breast cancer tissue
The expression level of MMP-7 mRNA was higher in nor-
mal breast tissue than in breast cancer tissue, both in
grade 2 (p = 0,008) and grade 3 (p = 0,04) (Figure 2, Table
4). Interestingly, the expression level of MMP-7 mRNA
was lower in grade 2 compared to grade 3 tumors (p =
0,0115) (Figure 2, Table 4).BMC Cancer 2009, 9:188 http://www.biomedcentral.com/1471-2407/9/188
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MMPs with equal expression in normal breast tissue and breast 
cancer tissue
In contrast to the abovementioned MMPs, an equal
expression of mRNA was detected in normal breast and
breast cancer tissue for MMPs -2, -3, -8, -10, -12, -14, -15,
-16, -17, -19, -23, -24 and -27 (Figure 1 and 2). However,
for MMP-8, -10, -12, -14 and -24 a diverse expression pro-
file was identified in the tissue samples analyzed. In some
tumor samples, a very strong expression was detected,
whereas in others no expression could be identified. In
addition, the expression level of MMP-21 and -25 was
very low in normal and tumor tissues. Therefore, their
expression was not quantified densitometrically.
MMPs, which showed obvious changes in their expression
in breast cancer tissue in comparison to normal breast tis-
sue could have an influence on breast cancer develop-
ment. Therefore we analyzed them on protein level
further.
Expression of MMP protein in normal breast tissue and 
breast cancer tissue
To confirm the results obtained by RT-PCR on protein
level, proteins were isolated from the same tissue samples,
which were used for the mRNA extraction. Using specific
antibodies against MMPs (listed in Table 3) a distinction
between the latent pro-form and the active form of the
MMPs was possible. Results of Western blots are summa-
rized in Figure 3 and boxplot analyses of the densitomet-
rically quantified MMP proteins are shown in Figure 4.
Corresponding p-values are listed in Table 5.
For MMP-1, -8, -10, -11, -12 and -15 both, expression of
proMMP and active MMP were significantly higher in
breast cancer tissue compared to normal breast tissue (e.g.
expression of proMMP-1 was higher in breast cancer tissue
grade 2 (p = 0,0007) and grade 3 (p = 0,0027) when com-
pared to normal breast tissue; Figure 4). All MMPs (except
proMMP-19 and proMMP-23 analyzed showed a signifi-
cantly higher expression of their latent form in breast can-
cer tissue in comparison to normal breast tissue.
Furthermore, for MMP-19 and -23 a significantly higher
expression of the active protein could be observed in
breast cancer tissue grade 2 when compared to normal
breast tissue (Figure 4, Table 5). For MMP-27, four bands
at approximately 74, 58, 53 and 50 kDa could be observed
(Figure 3). For MMP-28 five bands at approximately 62,
58, 50, 48 and 46 kDa were detected and all of them
showed a significantly higher expression in breast cancer
tissue, either grade 2 or grade 3, when compared to nor-
mal breast tissue (Figure 4).
Immunostaining of tissue samples
To identify the specific localization of cells expressing
MMPs within the tumor sample, we performed immuno-
histochemistry on paraffin embedded sections and breast
cancer tissue grade 3 that were directly adjacent to the sec-
tions used for RT-PCR and Western blot. Based on the
results of Western blots, we performed immunostaining
with antibodies against those MMPs that demonstrated a
specific expression pattern related to breast cancer devel-
opment. Immunostaining with MMP-1, -2, -3, -10, -11, -
13, -14, -15 and -19 antibodies corroborates the findings
of the Western blot analysis. Typical immunostaining
results are shown in Figure 5.
Table 4: P-values obtained by comparison of the MMP-mRNA 
expression between normal breast tissue and breast cancer 
tissue grade 2 and grade 3 respectively (Man-Whitney-U-Test)
NB-G2 NB-G3 G2-G3
MMP-1 p < 0,01 ns ns
MMP-2 ns ns ns
MMP-3 ns ns ns
MMP-7 p < 0,01 p < 0,05 p < 0,05
MMP-8 ns ns ns
MMP-9 p < 0,05 p < 0,05 p < 0,05
MMP-10 ns ns ns
MMP-11 p < 0,001 p < 0,05 ns
MMP-12 ns ns p < 0,05
MMP-13 p < 0,01 ns ns
MMP-14 ns ns ns
MMP-15 ns ns ns
MMP-16 ns ns ns
MMP-17 ns ns ns
MMP-19 ns ns ns
MMP-23 ns ns ns
MMP-24 ns ns ns
MMP-27 ns ns ns
MMP-28 ns p < 0,05 ns
ns = not significantBMC Cancer 2009, 9:188 http://www.biomedcentral.com/1471-2407/9/188
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Expression of MMP mRNA in human normal breast and breast cancer tissue analyzed by semiquantitative RT-PCR Figure 1
Expression of MMP mRNA in human normal breast and breast cancer tissue analyzed by semiquantitative RT-
PCR. Total mRNA from normal breast, breast cancer tissue grade 2 (G2) and breast cancer tissue grade 3 (G3) samples was 
used as template for RT-PCR analysis. Primers used in PCR reactions were designed in flanking exons, specific for each MMP 
transcripts (primer sequences are listed in Additional file 2). The gene porphobilinogen deaminase (PBGD) was used as internal 
loading control and the amount of each cDNA was normalized to the amount of PBGD. Genomic DNA amplified by the 
primer pair as well served as positive control (+).BMC Cancer 2009, 9:188 http://www.biomedcentral.com/1471-2407/9/188
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Boxplot analysis of densitometrically quantified expression of MMP mRNA Figure 2
Boxplot analysis of densitometrically quantified expression of MMP mRNA. The expression level of each gene was 
normalized to the corresponding expression of PBGD. For each MMP three boxes are mapped: expression in normal breast 
tissue (white box), in grade 2 tumors (G2) (light grey box) and in grade 3 tumors (G3) (dark grey box). Black line within the 
box represents the median, boxes show the quartiles and bars indicate the minimum and maximum value.
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To demonstrate that higher amounts of MMP protein in
Western blot analysis were not only caused by the higher
proportion of epithelial cells in tumor tissue in compari-
son to normal breast tissue we performed immunostain-
ing of normal breast tissue sections as well.
For MMP-1 the staining showed a clear predominance for
the nuclei of tumor cells with a slight additional staining
in the tumor cell's cytoplasm. A weak staining was found
in the surrounding stromal/endothelial and immune cells
(Figure 5A). In contrast to this no staining of MMP-1 was
found in normal breast tissue. Nuclei of tumor cells were
also stained with MMP2. However, herein the cytoplasm
of tumor cells showed a strong signal and even several
stromal cells were found to be clearly positive (Figure 5C).
MMP-2 was also found in the cytoplasm of normal breast
endothelial cells, albeit not in their nuclei (Figure 5D).
Immunostaining of MMP-3 showed a slight staining of
the tumor cell's cytoplasm with no staining of the sur-
rounding stromal and immune cells (Figure 5E). The cyto-
plasm of normal breast endothelial cells showed only a
slight positivity for MMP-3. For MMP-10, nuclei and cyto-
plasm of tumor cells were positive, whereas no staining
was found for stromal and immune cells (Figure 5G). The
cytoplasm of tumor cells expressed a high amount of
MMP-11 with several adjacent stromal cells being posi-
tive, too (Figure 5I). As opposed to this, expression of
MMP-11 could not be detected in normal breast tissue.
For MMP-13 a weak to moderate staining of the cyto-
plasm and nuclei of tumor cells and, in addition of the
cytoplasm of normal breast cells was found (Figure 5K
and 5L). Staining of MMP-14 was clearly restricted to the
cytoplasm of tumor cells and only very weak in stromal
cells (Figure 5M). Again, no MMP-14 could be detected in
normal epithelial breast cells. MMP-15 showed a strong
staining in the cytoplasm of tumor cells with additional
slightly staining of few stromal cells and in some nuclei of
tumor cells (Figure 5O). A clear predominant staining of
tumor cell's cytoplasm was found for MMP-19 (Figure
5Q). In normal epithelial breast cells only a slight staining
of the cytoplasm could be found for MMP-15 and -19.
Expression of MMP mRNA and protein in breast cancer 
cell lines
The expression of all human MMPs, which are identified
till now, was analyzed in four cell lines: MCF-7, MDA-MB-
468, BT 20 and ZR 75/1. Semiquantitative RT-PCR and
Western blot results are summarized in Figure 6 and Fig-
ure 7 and analyses of densitometrically quantified expres-
sion of MMP mRNAs and proteins are shown in Table 6
and Table 7, respectively.
For MMP-13, -14, -15, -17, -23 and -28, mRNA expression
was detected in all four cell lines investigated. By Western
blot, inactive and active forms of MMP-13, -23 and -28
could be detected to different amounts, whereas for MMP-
Table 5: P-values obtained by comparison of the MMP-protein 
expression between normal breast tissue and breast cancer 
tissue grade 2 and grade 3 respectively (Man-Whitney-U-Test)
NB-G2 NB-G3 G2-G3
ProMMP-1 p < 0,001 p < 0,01 ns
MMP-1 p < 0,05 p < 0,05 ns
proMMP-2 p < 0,01 p < 0,01 ns
M M P - 2 n sn sn s
proMMP-3 p < 0,01 p < 0,01 ns
M M P - 3 n sn sn s
proMMP-7 p < 0,01 ns ns
M M P - 7 n sn sn s
proMMP-8 ns p < 0,05 p < 0,01
MMP-8 ns p < 0,05 p < 0,001
proMMP-9 p < 0,001 p < 0,01 ns
M M P - 9 n sn sn s
proMMP-10 p < 0,001 p < 0,001 ns
MMP-10 p < 0,01 p < 0,01 p < 0,05
proMMP-11 p < 0,01 p < 0,001 ns
MMP-11 p < 0,01 p < 0,001 ns
proMMP-12 p < 0,05 p < 0,01 ns
MMP-12 p < 0,01 p < 0,01 ns
proMMP-13 ns p < 0,01 ns
MMP-13 ns ns ns
proMMP-15 p < 0,01 p < 0,01 ns
MMP-15 p < 0,01 ns ns
p r o M M P - 1 9 n sn sn s
MMP-19 p < 0,01 ns ns
p r o M M P - 2 3 n sn sn s
MMP-23 p < 0,05 ns ns
proMMP-24 p < 0,01 p < 0,001 ns
proMMP-26 p < 0,001 p < 0,001 ns
MMP-27 (74 kDa) ns p < 0,01 p < 0,05
MMP-27 (58 kDa) ns ns p < 0,05
MMP-27 (53 kDa) ns ns ns
MMP-27 (50 kDa) p < 0,001 p < 0,001 p < 0,01
MMP-28 (62 kDa) p < 0,001 p < 0,001 ns
MMP-28 (58 kDa) p < 0,05 p < 0,01 ns
MMP-28 (50 kDa) p < 0,001 p < 0,001 ns
MMP-28 (48 kDa) ns p < 0,01 ns
MMP-28 (46 kDa) ns p < 0,001 ns
ns = not significantBMC Cancer 2009, 9:188 http://www.biomedcentral.com/1471-2407/9/188
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Expression of MMP protein in human normal breast and breast cancer tissue analyzed by Western blot Figure 3
Expression of MMP protein in human normal breast and breast cancer tissue analyzed by Western blot. Protein 
lysates were isolated from normal breast, breast cancer tissue grade 2 (G2) and breast cancer tissue grade 3 (G3). Protein sam-
ples were separated by polyacrylamide gel electrophoresis and expression of MMP proteins was visualized using specific anti-
bodies (listed in Table 3). β-actin was used as internal loading control. Inactive (latent) and active forms of MMP proteins are 
indicated with arrows.BMC Cancer 2009, 9:188 http://www.biomedcentral.com/1471-2407/9/188
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Boxplot analysis of densitometrically quantified expression of MMP protein Figure 4
Boxplot analysis of densitometrically quantified expression of MMP protein. Protein levels were normalized to the 
corresponding expression of β-actin. For each MMP six boxes are mapped. The first three boxes are representing the expres-
sion of the inactive MMP form (white box: expression in normal breast tissue, light grey box: expression in grade 2 (G2) and 
dark grey box: expression in grade 3 (G3) breast cancer tissue). The remaining three boxes represent the expression of the 
active MMPs. The line within the boxplot corresponds to the median value, the box length to the interquartile range, and bars 
indicate the smallest and largest observations.
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14 and 15 only the zymogens could be identified in all
four cell lines. mRNA of MMP-3, -8 and -24 was identified
in the MDA-MB-468 cell line only. Whereas on protein
level only the inactive form of these three MMPs was
detected. In this cell line, the inactive form of MMP-24
was also identified by Western blot. Only BT-20 was neg-
ative for MMP-9 by RT-PCR. However, on protein level,
the pro- and active forms of MMP-9 were detected in the
MDA-MB-468 cell line only. For MMP-1, strong mRNA
expression was detected in the MDA-MB-468 cells and
moderate to weak expression in MCF-7 and BT 20. Corre-
sponding to this, on protein level, the active form of
MMP-1 could be detected in all three cell lines. The strong
MMP-2 mRNA expression correlated with a strong expres-
sion of proMMP-2 in the MDA-MB-468 and BT 20 cell
lines, whereas the active form of MMP-2 could not be
detected in any of the breast cancer cell lines tested. For
MMP-11 both, inactive and active forms could be detected
in all samples analyzed. Diverse expression patterns were
detected for the mRNA of MMP-16, -19 and -25. A weak
Immunostaining of MMP expression on paraffin embedded breast cancer tissue sections Figure 5
Immunostaining of MMP expression on paraffin embedded breast cancer tissue sections. MMP-1, -2, -3, -10, -11, -
13, -14, -15 and -19 expression (brown colour) in normal breast tissue and breast cancer tissue grade 3 (G3) was visualized 
using specific antibodies (listed in Table 3). Staining was predominantly restricted to the cytoplasm and nuclei of tumor cells, 
whereas staining of stromal cells was rare, e.g. immunostaining of MMP-1, -2 and -10 shows a clear preference for the tumor 
cell nuclei with slight to moderate additional staining of the cytoplasm of tumor cells (A, C, G). MMP-13 showed a weak to 
moderate staining of the tumor cells cytoplasm as well as a staining of the cytoplasm of normal breast cells (K and L). MMP-15 
showed a strong staining in the cytoplasm and in some nuclei of tumor cells and additional slight staining of stromal cells (O). 
MMP-11 and -19 staining was strong in the cytoplasm of tumor cells with additional slight staining of stromal cells and some 
nuclei of tumor cells (I and Q). MMP-3 and -14 showed a clear predominant staining of the tumor cells cytoplasm (E and M). 
Immunostaining of normal breast tissue served as control. Except MMP-13 (L), low to no staining for the abovementioned 
MMPs was found in normal breast tissue. Tissue stained with an irregular antibody served as negative control (S and T). Magni-
fication: ×250 for all pictures, ×400 for detail included into the upper right corner adjacent to the corresponding tumor tissue 
picture; ×400 for HE-staining included into the bottom right corner adjacent to the corresponding tumor tissue picture; 
brown: DAB, blue: hematoxylin counter stain, purple: hematoxylin-eosin counter stain.BMC Cancer 2009, 9:188 http://www.biomedcentral.com/1471-2407/9/188
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expression of proMMP-19 and a normal to strong expres-
sion of active MMP-19 was detected in the MDA-MB-468
and MCF-7 cell lines. For the remaining MMPs, no expres-
sion could be detected in all four breast cancer cell lines
by semiquantitative RT-PCR analysis.
Immunocytochemistry of cell lines
In order to confirm the obtained results of the Western
blot analysis we performed an immunocytochemical
analysis of MMP-1, -2, -3, -11, -13, -14, -15 and -19 on
MDA-MB-468 cells. For these MMPs, MDA-MB-468 cells
showed the strongest protein expression using Western
Blot analysis and therefore seemed to be the most prom-
ising cell line for the immunocytochemical analysis.
Table 6: Relative expression of MMP mRNA in different breast 
cancer cell lines
MCF-7 MDA-MB 468 BT 20 ZR 75/1
MMP-1 + +++ ++ 0
MMP-2 0 +++ ++ 0
MMP-3 0 +++ 0 0
MMP-7 0 0 0 0
MMP-8 0 (+) 0 0
MMP-9 (+) (+) 0 (+)
MMP-10 0 0 0 0
MMP-11 + + 0 +++
MMP-12 0 0 0 0
MMP-13 + ++ +++ ++
MMP-14 (+) +++ (+) ++
MMP-15 ++ + ++ ++
MMP-16 + + 0 ++
MMP-17 ++ + + +++
MMP-19 ++ ++ 0 0
MMP-20 0 0 0 0
MMP-21 0 0 0 (+)
MMP-23 ++ +++ +++ +
MMP-24 0 ++ 0 0
MMP-25 0 (+) 0 +
MMP-26 0 0 0 0
MMP-27 0 0 0 0
MMP-28 ++ + + +
0 = no expression, (+) = very weak expression, + = weak expression, 
++ = moderate expression, +++ = high expression
Table 7: Relative expression of MMP protein in different breast 
cancer cell lines
MCF-7 MDA-MB 468 BT 20 ZR 75/1
proMMP-1 0 0 0 0
MMP-1 + ++ + 0
proMMP-2 0 +++ +++ 0
MMP-2 0 0 0 0
proMMP-3 0 ++ 0 0
MMP-3 0 (+) 0 0
proMMP-8 0 ++ 0 0
MMP-8 0 0 0 0
proMMP-9 0 (+) 0 0
MMP-9 0 + 0 0
proMMP-11 (+) + 0 (+)
MMP-11 ++ + (+) +
proMMP-13 0 (+) (+) 0
MMP-13 (+) +++ + +
proMMP-14 (+) (+) (+) (+)
MMP-14 ++ ++ ++ +
proMMP-15 ++ ++ + +
MMP-15 0 (+) (+) 0
proMMP-19 + + 0 0
MMP-19 ++ +++ 0 0
proMMP-23 + + 0 0
MMP-23 ++ (+) + 0
proMMP-24 (+) + (+) (+)
MMP-24 0 0 0 0
MMP-28(62) + ++ (+) +
MMP-28(58) +++ 0 0 +++
MMP-28(50) 0 0 0 0
MMP-28(48) 0 0 0 0
MMP-28(46) 0 0 0 0
0 = no expression, (+) = very weak expression, + = weak expression, 
++ = moderate expression, +++ = high expression.BMC Cancer 2009, 9:188 http://www.biomedcentral.com/1471-2407/9/188
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Albeit MMP-1, -2 and -13 did not stain with either the
MDA-MB cell line or with control cells, immunocyto-
chemistry of the MDA-MB-468 cell line corroborates the
results obtained by Western blot analysis. Results are
shown in Figure 8.
Weak cytoplasmatic positivity was seen in all vital cells for
MMP-3, which in addition was found in the majority of
the nuclei, too (Figure 8B). A moderate to strong expres-
sion of MMP-11 and -14 was identified in nearly all MDA-
MB-468 cells (Figures 8C and 8D). MMP-15 was highly
expressed in all cells (Figure 8E) and MMP-19 showed a
clear positivity in all cells, too (Figure 8F). In both cases,
MMPs were localized in the cytoplasm.
Discussion
Breast cancer is an epithelial tumor with high invasive and
metastatic potential. Poorly differentiated tumors (G3)
seem to have a higher invasive potential resulting in a
higher frequency of lymph node metastases and lymphang-
iosis carcinomatosa than well differentiated tumours (G1)
[40]. These aspects were also found in the G3 tumor patient
group investigated in this study (Table 1).
In our study we focused on the expression analysis of
human specific matrix metalloproteinases (MMPs) in
breast cancer specimens. The expression analysis showed
three different expression patterns: high, low or equal
expression of MMPs in breast cancer tissue compared to
normal breast tissue. For the three collagenases, MMP-1, -
8 and -13, the first type of the expression pattern was iden-
tified. Our data about MMP-1 are in correlation with pre-
viously published results [5,18,20,41]. We found the
increase of the expression of latent and active protein
forms of MMP-1 to be related to higher tumour grade.
This finding fits with previous published data, reporting
on a shortened relapse-free-survival in breast cancer
patients with high expression of MMP-1 [15]. Published
data about the site of the MMP-1 production are contra-
dictory [42]. However, we showed that MMP-1 expression
is clearly restricted to the tumour cells, thus confirming
the findings of Iwata et al. [41]. For MMP-8, some studies
indicate its inhibitory effect on building metastatic forma-
tions [17,43], and no correlation between MMP-8 expres-
sion in breast cancer and negative prognostic factors was
found using ELISA [44]. In contrast to this, we found a sig-
nificant higher expression of pro- and active MMP-8 in
breast cancer compared to normal breast tissue. A correla-
tion between the high expression of MMP-13 in breast
cancer tissue and a higher rate of distant metastases, poor
prognosis and in addition a higher expression of MMP-13
in early stage tumors was shown [15,45]. In accordance to
this, we also identified higher amounts of MMP-13 mRNA
and pro-form in breast cancer tissue. Similar to the find-
ings of Zhang and colleagues [45], we identified MMP-13
Expression of MMPs in different human breast cancer cell  lines analyzed by semiquantitative RT-PCR Figure 6
Expression of MMPs in different human breast cancer 
cell lines analyzed by semiquantitative RT-PCR. Total 
RNA from breast cancer cell lines MCF-7, MDA-MB-468, BT 
20 and ZR 75/1 was extracted and used as template for RT-
PCR analysis. Primers, specific for each transcript, were 
designed in flanking exons (see Additional file 2: primer 
sequences), resulting in longer amplicons if human genomic 
DNA was amplified (positive control (+)) and in shorter 
amplicons representing cDNAs. The gene PBGD was used as 
internal loading control and amounts of cDNA were normal-
ized to the amount of PBGD for each sample.BMC Cancer 2009, 9:188 http://www.biomedcentral.com/1471-2407/9/188
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protein to be predominately expressed in the cytoplasm of
tumor cells. The expression of the two gelatinases, MMP-
2 and MMP-9, in breast cancer is well investigated in
many studies using different methods
[13,16,19,20,41,46]. Our Western blot data showed a sig-
nificant increase of proMMP-2 expression in tumor tissue,
which is in accordance with data described [15,19,46]. In
addition, MMP-2 staining was specific for nuclei and cyto-
plasm of tumor cells. This is in accordance with other
studies, verifying MMP-2 to be an unfavorable prognostic
factor in breast cancer [5,13]. Our findings about the high
expression of MMP-9 in the specimens analyzed are in
accordance with data published by Przybylowska and col-
leagues, who found increased levels of MMP-9 to correlate
with G3 breast cancer [20]. In contrast, studies of Jones
and Rhako failed to demonstrate any association between
the expression of MMP-9 in carcinoma or stromal cells
and clinicopathological parameters using immunohisto-
chemistry [47,48]. These differences might be due to dif-
ferent detection methods used. For the matrilysin MMP-7
only few contradictory data are available suggesting that
its role in breast cancer has not been brightly investigated
yet [15,16,19,42]. We also found divergent data concern-
ing the expression of MMP-7 in our tissue samples. While
the expression of MMP-7 mRNA was significantly lower in
breast cancer tissue when compared to normal breast tis-
sue. Equal to higher expression levels of MMP-7 pro and
active forms in breast cancer tissue were detected. This
could be due to a regulation on the translational level,
resulting in low levels of MMP-7 mRNA in breast cancer
tissue and – as effect of a higher transcriptional rate in
breast cancer tissue – higher protein levels of MMP-7 in
breast cancer tissue. In accordance to this, the expression
of the latent form of MMP-7 was stronger than the expres-
sion of its active form in the analyzed samples, like in the
case of MMP-23 and -24, as mentioned above. Although
the amount of MMP-10 (stromelysin 2) on mRNA level
was equal in all analyzed samples, expression of its pro
and active protein form was significantly higher in breast
cancer samples.
Using immunohistochemistry we found a nuclear stain-
ing for MMP-1, -2 and -10, which is unusual, because
MMPs are considered to be cytoplasmatic or membrane-
bound proteins. The nuclear localization of the above-
mentioned MMPs could thus be an indication of further
new functional roles of MMPs. In accordance to this, an
atypical nuclear staining was also observed by Ip et al. for
MMP-14 in hepatocellular carcinoma [49]. In this immu-
nohistochemical study the nuclear localization of MMP-
14 was associated with aggressive tumor features includ-
ing poor prognosis.
In accordance to our data, that clearly show a significant
increase in the expression of MMP-11 mRNA, propeptide
Expression of MMPs in different human breast cancer cell  lines analyzed by Western blot Figure 7
Expression of MMPs in different human breast cancer 
cell lines analyzed by Western blot. Protein lysates 
were isolated from the four breast cancer cell lines and sepa-
rated by polyacrylamid gel electrophoresis. MMP proteins 
were visualized using specific antibodies, capable of recogniz-
ing both, the inactive and active forms of MMPs (arrows inac-
tive/active). β-actin was used as an internal loading control. 
Protein amounts were quantified using the Bradford method 
and normalized to the amount of β-actin for each sample.BMC Cancer 2009, 9:188 http://www.biomedcentral.com/1471-2407/9/188
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and peptide in breast cancer compared to normal breast tis-
sue, the studies of Pacheco and Kossakowska reported the
same expression pattern for this matrix metalloproteinase
[16,19]. For MMP-15 (MT2-MMP) no correlation between
its expression, positive axillary node status, distant metas-
tases and size of breast tumor was detected by immunohis-
tochemistry [22]. However, our data show a high
expression of its protein in breast cancer tissue for both,
latent and active forms. For another membrane bound
MMP, MMP-24, only the size of the latent protein was
known and its expression was found to be significantly
higher in breast cancer tissue. A putative active bandage was
detected at about 55 kDa; this could possibly be an active
breakdown product of MMP-24, although the precise size
of the active form of MMP-24 is not known till now. The
expression of its latent form was stronger than the expres-
sion of the putative active form in the analyzed samples.
The absence of activated MMPs in tumor samples is not
unique; this phenomenon was also observed for MMP-9 in
ovarian cancer [50]. Expression and activity of proMMP-9,
but not its active form, was shown in the aggressive form of
this tumor and could reflect the presence of inflammatory
cells, which promote tumor progression.
In an immunohistochemical study comparing normal
breast tissue and mammary gland tumors, Djonov and
colleagues found MMP-19 to be expressed in all benign
lesions, whereas no expression was found in tumor tissue
[51]. However, we found MMP-19 protein to be higher
expressed in cancer tissue although its mRNA was equally
expressed in all analyzed samples. These different findings
might be due to different antibodies used in both studies.
The same expression pattern was identified for the latent
and active forms of MMP-12, -27 and -28. Active MMP-23
protein showed also a higher expression in G2 compared
to normal breast specimens. However, similar to MMP-
24, expression of its active form was weaker than of the
latent form. Although the expression of MMP-27 mRNA
was lower in breast cancer samples, its protein showed a
diverse expression pattern in the analyzed samples.
To date there are very few publications on the most
recently described MMP-27 and -28, and only very little
information about their protein sizes.
Showing a statistical significant difference in the expres-
sion level between normal breast and breast cancer tissue
grade 2 and 3 it seems possible, that some of the putative
bandages of MMP-27 and -28 are playing a role in breast
cancer development. Because till now no precise sizes of
their breakdown products and putative active and inactive
forms are known, these differences in the expression level
between normal breast and breast cancer tissue can give us
a first sign that these two MMPs can be involved in tumor
progression.
A strong association between the expression of MMP-14
by stromal cells and poor prognosis for the patients was
found by Vizoso et al. using immunohistochemistry [15].
However, in our study we found MMP-14 mRNA to be
equally expressed in normal breast and breast cancer tis-
sue. These differences might be due to the different expres-
sion profiles of MMP-14 on mRNA and protein level.
Therefore MMP-14 mRNA could possibly be expressed on
equal levels in breast cancer tissue and normal breast tis-
sue. Differences in expression might also be caused on the
translational level. Using immunohistochemistry we
found MMP-14 protein to be localized in the cytoplasm of
tumor cells with only slight additional staining of the sur-
rounding stroma cells, whereas no staining in normal
breast tissue could be detected. One possible reason might
be a higher translational rate of MMP-14 in breast cancer
tissue. MMP14 plays an important role in the activation of
other MMPs [52]. For example, MMP-14 activates
proMMP-2 at the cell surface [52]. In our study, MMP-2
mRNA was ubiquitously expressed in all analyzed sam-
ples, but – however – without a clear correlation to the
expression of its activator, MMP-14.
Expression of MMPs in MDA-MB-468 cells analyzed by  immunocytochemistry Figure 8
Expression of MMPs in MDA-MB-468 cells analyzed 
by immunocytochemistry. MMP-3, -11, -14, -15 and -19 
expression (brown colour) in MDA-MB-468 cells was visual-
ized using specific antibodies (listed in Table 3). Cells stained 
with a non-specific primary antibody served as negative con-
trol (A). Magnification: ×400 for all pictures; brown: DAB, 
blue: hematoxylin counter stain.BMC Cancer 2009, 9:188 http://www.biomedcentral.com/1471-2407/9/188
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For the remaining MMPs there are only limited or no data
available in the literature about their expression in breast
cancer tissue. Some studies documented the expression of
MMP-3 in breast cancer [5,21,42]. In one of those, signif-
icantly higher amounts of proMMP-3 and equal amounts
of its active form in breast cancer tissue compared to nor-
mal breast tissue were found using zymography [5]. These
findings are in accordance with the results obtained in our
study. Furthermore, only a weak staining of MMP-3 was
found in tumor cells using immunohistochemistry, which
thus correlates with published results [5,41]. In contrast to
this Haupt et al. found MMP-3 to be located in the stromal
tissue that surrounds the epithelial tumor cells [21]. Ueno
and colleagues could not detect MMP-16 (MT3-MMP) in
breast cancer tissue using Northern blot analysis [22],
whereas we detected its mRNA in normal and breast can-
cer tissue by RT-PCR. These differences in MMP-16 detec-
tion could be due to the different sensitivity of the
methods used. MMP-17 (MT4-MMP) showed the same
expression pattern in all tissues analyzed. For MMP-26 no
expression could be found in normal mammary glands,
whereas a high expression could be identified in precursor
lesions (DCIS) using immunohistochemistry. Further, on
tumor progression to invasive carcinomas the expression
level of MMP-26 was described to decrease again [53].
This is partly in accordance to our results, as we did not
detect MMP-26 mRNA in breast cancer tissue G2 and G3,
though we could not detect MMP-26 mRNA in normal
breast tissue either. However, PCR products obtained by
amplification of the genomic DNA, which was used as
positive control, showed that PCR properly worked. As
MMP-26 could not be detected by PCR, we did not inves-
tigate its expression on protein level. Expression of MMP-
21 and MMP-25 was very low on mRNA level, whereas
MMP-20 showed no expression. Therefore we did not
investigate them in further.
Expression of MMPs in breast cancer cell lines
Since there is obvious evidence about the influence of
MMPs on the development of breast cancer, we studied
their expression pattern in four different breast cancer cell
lines, which could be used as a model system for the anal-
ysis of the regulation of MMP expression in this tumor
entity. Our analyses showed, that the MDA-MB-468 cell
line expresses sixteen out of twenty- three MMPs analyzed
on mRNA and protein level. Using immunocytochemistry,
we could confirm our data obtained by RT-PCR and West-
ern Blot analysis in this cell line, as we found a weak stain-
ing for MMP-3 in the cytoplasm and nuclei of the tumor
cells. A moderate to strong expression of MMP-11 and -14
was identified in nearly all MDA-MB-468 cells, too. MMP-
15 and -19 expression was clearly restricted to the cyto-
plasm of tumor cells using immunocytochemistry.
This is partly in contrast to the results obtained by Gim-
bernardi et al. [9] and Grant et al. [54], who studied the
expression of MMP-1, -2, -3, -7, -8, -9, -10, -11, -12, -13, -
14, -15, -16, -17, -18 and -20 by RT-PCR in 84 normal or
human cancer cell lines, including some breast cancer cell
lines such as BT 20, MCF-7, MDA-MB-468, ZR 75/1 and
T47D. They observed the expression of MMP-9, -10, -14
and -15 in MDA-MB-468 cells only, whereas we could
detect the expression of MMP-1, -2, -3, -8, -11, -16, -17
and -19 in this cell line too. In contrast to their findings,
we did not detect any expression of MMP-7 and MMP-10
on mRNA level. These differences might be due to differ-
ences in the sensitivity of the methods and primers used
and/or to cell culture conditions. Differences in MMP
expression profiles caused by different cell culture condi-
tions were recently shown [55]. Kousidou et al. observed
a higher expression of MMP-1 and MMP-11 in MCF-7, BT
20 and ZR 75/1 cell lines when cultured in serum-free
media, whereas expression of MMP-9 in these three cell
lines was higher when serum was added to the medium
[55]. Similar to this, in our serum-cultured cells, we
observed a weak to high expression for MMP-1, -2, -13, -
15, -17, -23 and -28 in BT 20 cells, whereas Gimbernardi
et al. detected MMP-15 only in this cell line. For the
remaining MMPs, no expression in BT-20 cells was
detected in our study.
Conclusion
In conclusion we identified MMP-1, -2, -8, -9 -10, -11, -12,
-13, -15, -19, -23, -24, -27 and -28 as matrix metallopro-
teinases which show a stronger expression in breast cancer
tissue compared to normal breast tissue and could thus
seem to be associated with breast cancer development.
Hence, all fourteen MMPs are candidates for future func-
tional analyses and potential targets for new therapeutic
agents for patients. Even though first clinical trials using
MMP-inhibitors were disappointing [56], this fact high-
lights the need for a better insight into the mechanisms by
which MMPs contribute to tumor invasion and building
metastatic formations. This will provide the basis for a
better understanding of the role of MMPs in the cellular
processes of tumor invasion and building of metastatic
formations.
In vitro studies can provide a model for further investiga-
tions dealing with the role of MMPs. Given the heteroge-
neity of tumors and their variable growth characteristics,
examination of several cell lines of varying properties on
the MMP expression is necessary. Our study demonstrates
that four analyzed breast cancer cell lines constitutively
express a wide variety of MMPs on mRNA and protein
level and could be candidates for in vitro model systems
studying the role of MMPs in breast cancer biology.BMC Cancer 2009, 9:188 http://www.biomedcentral.com/1471-2407/9/188
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